Brokers Offer Predictions for CervoMed FY2027 Earnings

CervoMed Inc. (NASDAQ:CRVO) – HC Wainwright issued their FY2027 earnings per share (EPS) estimates for CervoMed in a note issued to investors on Tuesday, March 17th. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings per share of ($2.30) for the year. HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.88) per share.

Several other research firms have also recently issued reports on CRVO. D. Boral Capital reiterated a “buy” rating and set a $31.00 price objective on shares of CervoMed in a research report on Monday. Chardan Capital upped their target price on shares of CervoMed from $15.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday. Cantor Fitzgerald began coverage on shares of CervoMed in a research note on Thursday, December 18th. They set an “overweight” rating for the company. Roth Mkm reduced their price target on shares of CervoMed from $19.00 to $11.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of CervoMed in a research note on Wednesday, January 21st. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.00.

CervoMed Trading Down 0.2%

NASDAQ CRVO opened at $4.23 on Wednesday. CervoMed has a 12 month low of $3.58 and a 12 month high of $16.94. The stock has a market cap of $39.17 million, a PE ratio of -1.42 and a beta of -0.77. The stock’s 50 day moving average is $5.21 and its 200 day moving average is $7.19.

CervoMed (NASDAQ:CRVO) last released its quarterly earnings data on Friday, March 13th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.09). The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.84 million. CervoMed had a negative return on equity of 96.04% and a negative net margin of 672.80%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Rhumbline Advisers grew its holdings in shares of CervoMed by 35.5% in the first quarter. Rhumbline Advisers now owns 5,830 shares of the company’s stock valued at $53,000 after purchasing an additional 1,526 shares in the last quarter. Marshall Wace LLP purchased a new stake in CervoMed during the second quarter valued at $76,000. XTX Topco Ltd bought a new position in CervoMed during the fourth quarter valued at $81,000. Jane Street Group LLC bought a new position in CervoMed during the fourth quarter valued at $88,000. Finally, GSA Capital Partners LLP purchased a new position in shares of CervoMed in the 3rd quarter worth $91,000. 25.15% of the stock is currently owned by institutional investors.

CervoMed News Summary

Here are the key news stories impacting CervoMed this week:

• Positive Sentiment: New clinical data presented at the AD/PD 2026 conference show that neflamapimod produced greater benefit in Dementia with Lewy Bodies (DLB) patients who have low plasma pTau181 (i.e., likely without Alzheimer’s co‑pathology). This can increase the perceived commercial and regulatory value of the program for a clearer DLB target population. GlobeNewswire: AD/PD 2026 Data
• Positive Sentiment: HC Wainwright reiterated a Buy and a $25 price target while trimming some near-term EPS forecasts but raising several quarterly and FY2026/FY2027 estimates overall (and raising some quarter estimates). The firm’s maintained Buy and higher longer‑term estimates support upside expectations. MarketBeat: HC Wainwright Notes
• Positive Sentiment: Chardan Capital raised its price target from $15 to $21 and kept a Buy rating, signaling investor conviction from another boutique healthcare analyst. TickerReport: Chardan Raise
• Positive Sentiment: D. Boral Capital published a Buy rating on CRVO, adding to the list of brokers expressing conviction in the story. American Banking News: Buy Rating
• Neutral Sentiment: Coverage notes and press summaries report the company was “flat” on Q4/FY results; no new material guidance or financing announcements were reported in those summaries. Market reaction may therefore hinge on interpretation of pipeline updates and analyst notes. BayStreet: Flat on Q4/FY
• Neutral Sentiment: Reported short‑interest data for March are effectively meaningless in the published entry (shows 0 shares / NaN change), so short‑squeeze or added short pressure is not an active driver based on that report.
• Negative Sentiment: Roth MKM lowered its price target from $19 to $11 (while still on Buy), which reduces near‑term analyst upside and could pressure sentiment among investors focused on published targets. Benzinga: Roth MKM PT Cut
• Negative Sentiment: HC Wainwright trimmed its Q1 2026 EPS estimate (worse near‑term quarterly view), underscoring continued execution and cash‑burn risk until definitive late‑stage data or partnering/financing alleviates funding concerns.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc was founded in 2010 and is headquartered in Boston, Massachusetts.